The best Part D plan is the one that covers your actual drugs
A Part D comparison should begin with the medicines you take, not with the company name or the monthly premium. Each plan has its own formulary, and the same drug can be treated differently across plans. One plan may place a medicine on a preferred tier with a modest copay, another may charge coinsurance on a higher tier, and a third may require prior authorization or step therapy. Those differences can easily outweigh a small premium advantage.
Build the shortlist with your current medication list. Use the exact drug name, strength, dosage form, quantity and refill frequency. Confirm that every important medicine is covered for the current plan year, then check the tier and any restriction codes. A generic substitute can change the economics, but only if your prescriber agrees that the alternative is appropriate. Do not assume a cheaper listed drug is automatically interchangeable with what you use now.
This is also why our Best page ranks Part D portfolios rather than pretending that one regional plan is nationally best for everyone. Company-level research can identify useful plan families, strong pharmacy access, clear shopping tools and credible benefit designs. The final enrollment decision still belongs to the exact PDP in your region because that exact plan controls the formulary and cost-sharing details.
If one plan clearly covers your medicines better than the rest, give that fact more weight than a small difference in MarketReview Rating. The rating is editorial context. Your prescriptions determine whether the coverage actually works.
When you compare portfolios on this page, treat the Best For label as a starting point rather than a prescription. It highlights a portfolio-level strength. It does not mean every regional plan under that company will beat every alternative for your specific drugs, pharmacy and assistance status.
Compare total yearly drug cost, not the premium alone
A low premium is attractive because it is simple and certain. You see the number every month. Part D costs are not that simple. A plan with a lower premium can have a higher deductible, less favorable tier placement or more expensive cost sharing at the pharmacy you use. Another plan may charge more each month but produce lower annual spending for a person with several regular prescriptions.
Estimate the full year whenever possible. Add twelve months of plan premiums to the expected deductible exposure and the expected copays or coinsurance for your prescriptions. If your plan comparison tool provides a monthly spending pattern, look at that too. Some plans front-load costs through the deductible, while others distribute spending more evenly. The annual total tells you which plan appears cheaper; the monthly pattern tells you whether the cash flow is comfortable.
For 2026, Medicare drug plans cannot have a deductible above $615, and out-of-pocket spending on covered Part D drugs reaches catastrophic coverage at $2,100. Those federal parameters improve the downside picture, but they do not make plan design irrelevant. Many people will not reach the $2,100 threshold. Their real spending will be driven by the premium, deductible treatment, tier structure and pharmacy pricing they encounter before catastrophic coverage begins.
When two plans are close, test the comparison under a realistic alternative scenario. What happens if you add one brand-name medicine during the year? What if you move a maintenance drug to mail order? You do not need to predict every future prescription, but a small stress test can show whether the apparent winner depends on an unusually narrow set of assumptions.
Be careful with cost estimates based on only one refill. Part D can treat 30-day retail, longer retail supplies and mail order differently. A plan that wins on one month's copay may not win across a year of recurring fills. Use the supply pattern you actually expect to use.
Formulary placement can matter more than a lower monthly premium
Part D formularies organize covered drugs into tiers, but tier labels are only a starting point. The decision value comes from the cost sharing and restrictions attached to the exact medicine. A Tier 1 generic with a very low preferred-pharmacy copay can be inexpensive even before you consider the premium. A non-preferred or specialty drug can create much more spending, especially when the plan uses coinsurance rather than a fixed dollar copay.
Compare each important drug row by row. Check whether the medicine is generic, preferred brand, non-preferred or specialty under the plan. Then check whether the deductible applies to that tier. Some 2026 plans exempt lower tiers from the deductible or offer a zero deductible for selected tiers. That can make the headline deductible less important for someone who takes only lower-tier medicines, while it remains highly relevant for another person whose prescriptions sit on higher tiers.
Coinsurance deserves special attention because it is a percentage rather than a fixed amount. A 20% or 25% share can behave very differently depending on the negotiated price of the drug. If the comparison tool provides estimated retail or plan prices, use them. A simple label such as "25% coinsurance" does not tell you the dollar amount without the price underneath it.
Do not overvalue the size of a formulary either. A plan can cover thousands of drugs and still be a poor fit if the few medicines you need are treated unfavorably. The better question is not how many drugs the plan covers in total. It is whether the plan covers your medicines on workable terms.
If a medicine is missing from the formulary, price comparisons for that plan become secondary. Ask whether an exception or covered alternative is realistic, but do not build the enrollment decision around an exception that has not been granted. A covered drug on workable terms is more dependable than a hypothetical appeal outcome.
Preferred pharmacy status can change the math
Many Part D plans use preferred and standard network pharmacies. The pharmacy can therefore change your cost even when the drug and plan stay the same. A preferred location may offer lower copays or coinsurance for selected tiers, while a standard network location can cost more. Out-of-network fills are generally a different problem and may be covered only in limited circumstances.
Run the comparison using the pharmacy you actually visit. Then, if you are willing to switch, test a convenient preferred pharmacy. The difference may be modest for inexpensive generics and more meaningful for other drugs. A company advertising a large pharmacy network is useful context, but network size alone does not answer whether your local store receives preferred cost sharing under the exact plan.
Mail order can create another pricing path. Several major Part D carriers promote home-delivery options for maintenance medicines, sometimes with lower cost sharing for longer supplies. Compare the exact medicine and supply length. Do not assume that mail order is always cheaper, and do not choose a plan primarily for home delivery if you prefer local pickup or need frequent medication changes.
Pharmacy networks can change during a plan year. Before enrollment, use the current directory and confirm the specific location, not only the chain name. If you rely on an independent pharmacy, specialty pharmacy or a particular home-delivery service, verify that relationship directly. Part D shopping is partly a drug comparison and partly a distribution-network comparison.
People who split time between locations should repeat this pharmacy check in both places. National branding does not guarantee identical preferred-pharmacy convenience everywhere. A plan can work extremely well near one home and create more standard-cost fills near another, even though both locations sit inside the broader network.
The deductible matters differently depending on which tiers it applies to
The 2026 maximum Part D deductible is $615, but the maximum does not mean every plan charges $615 or applies the deductible to every covered drug. Some plans have no deductible. Others have the full deductible but exempt lower tiers. Still others use a lower deductible on higher tiers. That design can materially change early-year spending.
Suppose two plans both show a $615 deductible. If one exempts the generic tiers you use and the other applies the deductible to those drugs, the same headline number produces a different experience. The reverse can be true for someone who takes an expensive brand or specialty medicine. A generous generic-tier exemption may provide little benefit if most of that person's spending occurs on a tier where the deductible still applies.
Read the deductible together with the tier table. Ask three questions: what is the deductible, which tiers does it apply to, and what happens after it is satisfied? That sequence gives you much more information than comparing deductible numbers by themselves.
A zero-deductible plan can be attractive, especially for someone who expects meaningful prescription use early in the year. It is not automatically cheaper over twelve months. The premium and post-deductible cost sharing still matter. Treat the deductible as one piece of the annual-cost model rather than a standalone Best label.
When comparing plans, note the month in which you expect to satisfy the deductible, if at all. Someone filling several expensive prescriptions in January may experience the deductible very differently from someone whose lower-tier generics never trigger most of it. Timing is part of the budget impact.
Coverage rules can matter more than a low copay
A formulary listing does not always mean immediate, unrestricted coverage. Part D plans may use prior authorization, step therapy and quantity limits. Prior authorization can require the plan to approve coverage before it pays for the medicine. Step therapy can require trying a lower-cost drug first. Quantity limits can cap the amount covered over a defined period unless an exception is approved.
These rules matter most when a medication is clinically important and switching is difficult. A plan may show a favorable copay, but that copay has limited value if the member cannot satisfy the coverage rule or faces repeated administrative work. Check restriction codes for every important medicine, particularly high-cost or specialty drugs.
Medicare provides exception processes, and plans can offer transition fills in certain circumstances for new members whose current drugs are non-formulary or restricted. Those protections are useful, but they should not be mistaken for guaranteed permanent coverage. An exception request requires supporting information and can be denied. A transition supply is temporary.
If two plans have similar annual cost estimates, the cleaner access path can be a reasonable tie-breaker. This is an area where the cheapest-looking plan can lose after closer review. A slightly higher premium may be worth paying when it reduces a material access problem for a medicine you expect to take all year.
Keep the access question specific. Do not downgrade a plan simply because it uses prior authorization somewhere in its formulary. Focus on whether your medicines have restrictions and how those restrictions affect your treatment. The relevant burden is personal, not the raw number of restricted drugs in the plan.
The 2026 $2,100 out-of-pocket threshold changes high-cost-drug risk
The redesigned Part D benefit puts a clear annual limit on qualifying out-of-pocket spending for covered Part D drugs. In 2026, the threshold is $2,100. After the member reaches catastrophic coverage, there is no additional out-of-pocket cost sharing for covered Part D drugs for the rest of the calendar year. This is especially important for people who use expensive brand-name or specialty medicines.
The threshold should change how you interpret plan differences, not erase them. A person likely to reach $2,100 may care about how quickly the plan reaches that point, the premiums paid along the way, formulary access and whether all critical prescriptions are covered. A person with modest drug spending may never reach catastrophic coverage, so lower-tier copays and preferred-pharmacy pricing remain the larger part of the decision.
Premiums do not count toward the Part D out-of-pocket threshold. Neither does every dollar spent outside the plan on a drug that is not covered. That means a high-cost non-formulary medicine can still create a major financial problem even though Part D has an annual cap for covered drug spending. Coverage remains the first test.
For high-cost-drug users, compare the whole-year scenario and the path through the year. The Medicare Prescription Payment Plan can spread eligible out-of-pocket costs across monthly bills, but it does not reduce the total amount owed. Cash-flow assistance and lower total cost are separate questions.
The cap also makes non-covered drug risk more visible. If an expensive medicine is excluded and no exception is approved, paying for it outside the plan may not receive the same protection as covered Part D spending. That is another reason the formulary check comes before a premium or rating comparison.
Extra Help changes how you should shop
People who qualify for Medicare Extra Help face a different Part D cost structure from members paying standard plan costs. Extra Help can reduce premiums, deductibles and prescription cost sharing. It also eliminates the Part D late enrollment penalty. Some carriers specifically position certain PDPs for people receiving Extra Help, so a general Best ranking should not replace a comparison using the assistance level that actually applies to you.
If you receive Extra Help, enter that information when using Medicare's plan comparison tools. A plan that looks expensive at standard cost sharing may be much more competitive under the subsidy. Conversely, a plan marketed around low standard premiums may not be the most useful choice once Extra Help changes the member's share.
Also distinguish Extra Help from the Medicare Prescription Payment Plan. Extra Help can reduce what you owe. The Payment Plan only changes when you pay eligible out-of-pocket prescription costs by spreading them over the remaining months of the calendar year. If you qualify for cost assistance, investigate the assistance first.
Do not assume Extra Help is the only program that can affect prescription costs. State Pharmaceutical Assistance Programs and other assistance may apply in some locations. Eligibility is personal and can change. The Part D plan still needs to cover the medicines and pharmacies that matter to you, but the financial comparison should reflect the assistance you actually receive.
If you are unsure whether you qualify for Extra Help, do not assume standard-cost estimates are final. Check eligibility through Medicare or Social Security and then rerun the comparison with the correct assistance status. The right subsidy information can materially change which PDP appears most affordable.
Use CMS Part D Stars as quality context, not as a drug-cost calculator
CMS Part D Star Ratings provide useful contract-level quality information, including measures tied to member experience, medication safety and plan operations. They are not a substitute for checking the formulary or estimating your prescription costs. A contract can have a stronger Star Rating while an exact regional plan is a worse fit for your medication list.
MarketReview keeps CMS Stars separate from the MarketReview Rating for the same reason. The two measures answer different questions. CMS Stars are an external Medicare quality signal at the contract level. The MarketReview Rating is an editorial assessment of the consumer-facing Part D portfolio, including the usefulness of the available plan designs, shopping context and other verified evidence. Neither number turns a regional PBP into a national cost promise.
Use quality information after the basic fit tests. First confirm your drugs, pharmacies, restrictions and expected cost. If two plans remain close, quality and service context can help distinguish them. That ordering protects against choosing a higher-rated company whose exact plan does not work for your prescriptions.
Star Ratings can also change by rating year, and contracts can change over time. Make sure you are looking at the current rating attached to the relevant contract rather than a historic company score. A familiar brand may operate multiple Medicare contracts, so brand recognition alone does not identify the rating that applies.
A lower CMS Star Rating is not automatically a reason to reject a plan that clearly fits your medications better, but it is information worth understanding. Look at it as one quality signal alongside the concrete plan fit. The final choice needs both workable drug coverage and acceptable plan administration.
Recheck the plan every year before you keep it
A good Part D plan this year is not automatically the best plan next year. Premiums, deductibles, formularies, tier placement, pharmacy networks and utilization rules can change. Your own prescription list can change too. Annual review is therefore part of responsible Part D shopping even when you are satisfied with your current company.
Start with the Annual Notice of Change and the next plan year's formulary. Re-enter your current prescriptions into a current comparison, then check the pharmacies you plan to use. Pay attention to a drug moving to a higher tier, a new prior authorization requirement, a pharmacy losing preferred status or a premium increase that changes the total annual cost.
You do not need to switch just because something changed. A plan may remain the best fit despite a higher premium, especially if it still covers your important drugs more favorably than alternatives. The purpose of the annual check is to replace assumption with current evidence.
The final choice should be easy to explain without referring to a ranking position. Your important medications are covered, the restrictions are manageable, your pharmacies work on favorable terms and the total expected cost fits your budget. Use the Best list to create a shortlist. Use the exact plan comparison to make the enrollment decision.
Save the medication list and pharmacy assumptions you used this year. They make the next annual review much faster and help you identify what truly changed. That prevents a new comparison from becoming a complete restart and makes it easier to focus on differences that could affect your actual spending or access.